The End of the Traditional Launch: How JCA, HTA Evolution and Pricing Pressures Are Driving Continuous Evidence Generation

For decades, pharmaceutical launch planning followed a familiar playbook. Clinical development generated the clinical evidence package, regulatory approval marked a critical milestone and HEOR and market access teams worked to secure reimbursement through health technology assessment (HTA) submissions and payer engagement. Evidence generation was organized around a series of launch-focused deliverables designed to support approval, pricing, HTA and reimbursement decisions.

Today, that model is being challenged.

The implementation of the European Union's Joint Clinical Assessment (JCA), growing demands for comparative and real-world evidence (RWE), increasing scrutiny of health care spending and renewed attention to international pricing policies are reshaping the relationship between evidence generation and commercialization. Together, these forces are compressing timelines, expanding evidence requirements and exposing the limitations of a model built around discrete evidence deliverables.

Manufacturers can no longer assume that a dossier developed for a single milestone will satisfy the evolving demands of HTA bodies, payers, providers and policymakers throughout a product’s life cycle. Success increasingly depends on the ability to continuously generate, synthesize, update and communicate evidence as stakeholder expectations evolve.

How JCA Is Raising the Bar for Evidence Readiness

The European Union's JCA represents one of the most significant changes to the HTA landscape in decades. By establishing a coordinated framework for clinical assessments across participating member states, the JCA aims to reduce duplication while promoting greater consistency in the clinical evaluation of innovative medicines.

For manufacturers, the implications extend well beyond procedural efficiency.

Historically, evidence strategies could be adapted market by market through engagement with individual HTA agencies. Under the JCA framework, evidence packages will be scrutinized through a shared assessment process, increasing the importance of getting evidence strategy right from the outset. Decisions once addressed sequentially across European markets must now withstand broader review, often within compressed timelines.

This shift is forcing organizations to align clinical development, epidemiology, HEOR, market access and medical affairs earlier in development. Comparator selection, end point strategy, patient segmentation and evidence synthesis plans must increasingly be designed with both regulatory and HTA requirements in mind.

As a result, launch readiness is becoming an early development capability rather than a late-stage commercialization activity.

The Growing Importance of Evidence Beyond Clinical Trials

At the same time, HTA bodies and payers are asking more complex questions than traditional clinical trials alone can answer.

While randomized controlled trials remain the gold standard for demonstrating efficacy and safety, reimbursement decision-makers increasingly seek evidence on comparative effectiveness, health care resource utilization, patient-reported outcomes, treatment adherence and long-term outcomes in routine clinical practice.

Stakeholders want to understand not only whether a therapy works, but how it performs relative to competing interventions and whether it delivers meaningful value within health care systems.

To answer these questions, manufacturers are relying on an expanding range of evidence-generation approaches, including systematic literature reviews, indirect treatment comparisons, network meta-analyses, burden-of-illness studies and real-world evidence studies. These methods help bridge the gap between regulatory evidence requirements and the broader evidence expectations of HTA agencies and payers.

Importantly, many evidence needs emerge following regulatory approval. New comparators enter the market, treatment pathways evolve and HTA agencies revisit prior decisions as additional data become available. Evidence packages that were sufficient at launch may no longer address the questions being asked a few years later.

Consequently, evidence generation must become an ongoing strategic capability that supports market access, reimbursement and value demonstration throughout the product life cycle.

How Pricing Pressures are Increasing Strategic Complexity

Evidence challenges are also intersecting with increasing pressure on pharmaceutical pricing.

International reference pricing systems, discussions around most-favored-nation pricing approaches and broader affordability concerns are placing greater emphasis on launch sequencing and market access planning. Decisions made in one market can have downstream implications elsewhere, elevating the strategic importance of evidence quality and timing.

Delays resulting from evidence gaps are no longer simply operational issues. They can influence reimbursement outcomes, pricing flexibility and broader market access strategies.

From Evidence Deliverables to Evidence Platforms

The cumulative effect of these changes is prompting a fundamental shift in how organizations think about evidence generation.

Historically, evidence activities were managed as standalone projects. Literature reviews, indirect treatment comparisons, value dossiers, economic models, HTA submissions and postlaunch studies were often commissioned independently by different teams and external partners. While effective in a milestone-driven environment, this approach can create duplication, inconsistent assumptions and fragmented knowledge.

Increasingly, manufacturers are moving toward platform-based approaches.

Rather than creating evidence assets for a single decision point, organizations are building integrated evidence ecosystems that connect data sources, evidence synthesis, economic modeling and ITC workflows, RWE generation and value communication capabilities. These platforms enable evidence assets to be continuously updated, reused and adapted as new questions emerge from regulators, HTA agencies, payers, providers and policymakers.

Organizations need the ability to rapidly assess evidence gaps, evaluate comparator strategies, update indirect treatment comparisons, refresh economic models and generate decision-relevant evidence across multiple markets.

A New Definition of Launch Excellence

The pharmaceutical industry has traditionally viewed launch as the handoff point between evidence generation and commercialization. Emerging HTA models suggest a different reality.

Today, launch is increasingly becoming the beginning of an ongoing cycle of evidence generation, evidence synthesis and value demonstration.

Organizations that continue to operate through siloed, project-based evidence models will struggle to meet the demands of JCA, evolving HTA expectations and growing pricing pressures. And those that invest in capabilities for continuous evidence generation will be best positioned to adapt to changing stakeholder requirements and demonstrate value over time.

The traditional launch is not disappearing, but its role is changing. Competitive advantage will depend less on the ability to produce launch deliverables and more on how to sustain a continuous, evidence-driven dialogue about value. The future belongs to organizations that view evidence not as a one-time output but as a strategic asset that must be actively generated, managed and leveraged throughout the product life cycle.

Chris Cameron, Ph.D., is chief scientific officer, global value & evidence at EVERSANA and a global thought leader in HEOR and HTA. Tim Reason is the cofounder of Estima Scientific, which recently merged with EVERSANA.